Daewoong Pharmaceutical Co., Ltd. Statistics
Want to see KR:069620 full AI Analyst Report?
Daewoong Pharmaceutical Co., Ltd. (069620) Stock Statistics & Valuation Metrics
Total Valuation
Daewoong Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 1.16T. The enterprise value is KRW 2.15T.
- Market Cap
- KRW 1.16T
- Enterprise Value
- KRW 2.15T
Share Statistics
Daewoong Pharmaceutical Co., Ltd. has 11,586,575 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 11,586,575
- Owned by Insiders
- ―
- Owned by Institutions
- 5.09%
Financial Efficiency
Daewoong Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 9.52%.
- Return on Equity (ROE)
- 0.19
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 9.52%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 875.63M
- Profits Per Employee
- 109.17M
- Employee Count
- 1,794
- Asset Turnover
- 0.66
- Inventory Turnover
- 2.44
Valuation Ratios
The current PE Ratio of Daewoong Pharmaceutical Co., Ltd. is 6.25. Daewoong Pharmaceutical Co., Ltd.’s PEG ratio is 0.06.
- PE Ratio
- 6.25
- PS Ratio
- 0.69
- PB Ratio
- 1.09
- Price to FCF
- -9.68
- Price to Operating Cash Flow
- 8.68
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Daewoong Pharmaceutical Co., Ltd. had revenue of 1.57T and earned 195.86B in profits. Earnings per share was 17021.00.
- Revenue
- 1.57T
- Gross Profit
- 812.85B
- Operating Income
- 195.51B
- Pretax Income
- 191.83B
- Net Income
- 195.86B
- EBITDA
- 245.78B
- Earnings Per Share (EPS)
- 17021.00
Cash Flow
In the last 12 months, operating cash flow was 134.37B and capital expenditures -254.07B, giving a free cash flow of -119.69B billion.
- Operating Cash Flow
- 134.37B
- Free Cash Flow
- -119.69B
- Free Cash Flow per Share
- -10329.90
Dividends & Yields
Daewoong Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 0.60%
- Dividend Per Share
- ―
- Dividend Yield
- 0.60%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.39%
- Earnings Yield
- 15.82%
Stock Price Statistics
- Beta
- 0.08
- 52-Week Price Change
- -42.06%
- 50-Day Moving Average
- 106516.00
- 200-Day Moving Average
- 132212.50
- Relative Strength Index (RSI)
- 42.05
- Average Volume (3m)
- 20.25K
Important Dates
Daewoong Pharmaceutical Co., Ltd. upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Daewoong Pharmaceutical Co., Ltd. as a current ratio of 1.24, with Debt / Equity ratio of 82.44%
- Current Ratio
- 1.24
- Quick Ratio
- 0.72
- Debt to Market Cap
- 0.41
- Net Debt to EBITDA
- 2.69
- Interest Coverage Ratio
- 15.67
Taxes
In the past 12 months, Daewoong Pharmaceutical Co., Ltd. has paid -1.08B in taxes.
- Income Tax
- -1.08B
- Effective Tax Rate
- -0.01
Enterprise Valuation
Daewoong Pharmaceutical Co., Ltd. EV to EBITDA ratio is 7.02, with an EV/FCF ratio of -16.36.
- EV to Sales
- 1.16
- EV to EBITDA
- 7.02
- EV to Free Cash Flow
- -16.36
- EV to Operating Cash Flow
- 14.57
Balance Sheet
Daewoong Pharmaceutical Co., Ltd. has KRW 150.90B in cash and marketable securities with KRW 952.75B in debt, giving a net cash position of -KRW 801.85B billion.
- Cash & Marketable Securities
- KRW 150.90B
- Total Debt
- KRW 952.75B
- Net Cash
- -KRW 801.85B
- Net Cash Per Share
- -KRW 69.21K
- Tangible Book Value Per Share
- KRW 102.85K
Margins
Gross margin is 51.88%, with operating margin of 12.18%, and net profit margin of 10.91%.
- Gross Margin
- 51.88%
- Operating Margin
- 12.18%
- Pretax Margin
- 10.00%
- Net Profit Margin
- 10.91%
- EBITDA Margin
- 16.57%
- EBIT Margin
- 12.10%
Analyst Forecast
The average price target for Daewoong Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 9.16%
- EPS Growth Forecast
- 96.95%
Scores
- Smart Score
- ―
- AI Score
- 62

